:

Xueting Zhu1, Yikun Wang2, Yizi He3

  • 1Graduate Collaborative Training Base of Hunan Cancer Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan,421001,China; Department of Lymphoma & Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, No. 283 Tongzipo Road, Yuelu District, Changsha, Hunan, China.

概括

多发性骨髓瘤 (MM) 细胞重新编程新陈代谢以推动进展和耐药性. 针对这些代谢脆弱性为MM患者提供了新的治疗和生物标志物策略.